PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Mon - Aug 15      Tue - Aug 16      Wed - Aug 17      Thu - Aug 18   

WEDNESDAY, AUGUST 17

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
INTRODUCTION TO A TREATMENT FOR ADULTS WITH ACUTE HEPATIC PORPHYRIA, INCLUDING ACUTE INTERMITTENT PORPHYRIA (SPONSORED BY ALNYLAM PHARMACEUTICALS)
Chicago Ballroom VI

Join Alnylam Pharmaceuticals for a presentation on a treatment for adults with acute hepatic porphyria (AHP) including acute intermittent porphyria (AIP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Presented by Dr. Ilene Weitz, this presentation will discuss a range of topics, including: AHP disease overview and pathophysiology Introduction to AHP treatment Mechanism of Action Efficacy and safety results from the Phase 3 Study and open-label extension Please join Alnylam Pharmaceuticals and Dr. Ilene Weitz, Professor of Clinical Medicine at the University of Southern California, to learn more about this treatment for adults with acute hepatic porphyria (AHP). Breakfast will be provided for attendees. This presentation is intended for US Healthcare Professionals only and no continuing education credits will be provided.



NOVEL INVESTIGATIONAL APPROACHES FOR HEMOPHILIA MANAGEMENT (SPONSORED BY SANOFI)
Chicago Ballroom IX-X

The symposium Novel Investigational Approaches for Hemophilia Management, organized by Sanofi, is intended for clinical and research experts in thrombosis, hemostasis, and vascular biology. Given the rapidly evolving therapeutic landscape in hemophilia management, there is a need for education on emerging treatments with novel mechanisms of action (MOA) and mechanisms of extension (MOE). The symposium will be presented in three parts: Part 1 will provide a brief overview of current hemophilia management and unmet needs Part 2 will describe the investigational molecule efanesoctocog alfa, with an MOE that overcomes the VWF-imposed half-life ceiling for FVIII replacement, and an overview of its clinical trial program Part 3 will present the MOA of the investigational siRNA molecule fitusiran, and will conclude with an overview of its clinical trial program.


8:15 - 9:15 AM
HEMOSTASIS
BLEEDING: NOT OTHERWISE SPECIFIED (B-DUC)
Chair/Organizer: Yasmina Abajas, Maria Santaella
Sheraton Ballroom I-III


9:00

Q&A.


8:15

THE IDEAL WORKUP FOR BLEEDING, NOS, AND PE
Ming Lim. University of Utah


8:30

A PRIMER ON CONNECTIVE TISSUE DISORDERS
Pamela Trapane. UF College of Medicine - Jacksonville


8:45

PATHOPHYSIOLOGY OF BLEEDING IN CONNECTIVE TISSUE DISORDERS
Rohith Jesudas. St. Jude Children's Research Hospital

8:15 - 9:15 AM
THROMBOSIS / BASIC SCIENCE
NOVEL TARGETS AND NOVEL USES FOR ANTICOAGULATION
Chair/Organizer: Vinai Bhagirath, Julie Jaffray
Sheraton Ballroom IV-V


8:15

DIRECT FACTOR XI ANTICOAGULANT TRIALS UPDATE
Noel Chan. McMaster University


8:30

FACTOR XI IN ATHEROSCLEROSIS
Owen McCarty. Oregon Health a Science University


8:45

DIRECT ORAL ANTICOAGULANTS IN PROTEINURIC KIDNEY DISEASE
Bryce Kerlin. Nationwide Children's / The Ohio State University College of Medicine


9:00

Q&A.

8:15 - 9:15 AM
LABORATORY
QUALITY ASSURANCE IN THE HEMOSTASIS LABORATORY
Chair/Organizer: Katrien Devreese, Kristi Smock
Chicago Ballroom VII


8:15

TEST MENU UPDATES FOR NEW HEMOPHILIA TREATMENTS
William Pickering. Labcorp Colorado Coagulation


8:30

ANTI-XA ACTIVITY ASSAYS AND UNFRACTIONATED HEPARIN MONITORING - SHOULD THIS BE THE STANDARD?
Karen Moser. University of Utah / ARUP Laboratories


8:45

LESSONS LEARNED FROM LABORATORY PRACTICE IN 2020
Morayama Gill. Cleveland Clinic


9:00

Q&A.

9:15 - 10:00 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


401

BREAKTHROUGH IN LABORATORY FUNCTIONAL TESTING OF HIT USING FLOW CYTOMETRY AND ARTIFICIAL INTELLIGENCE. TOWARDS AUGMENTED DIAGNOSTICS?
Matthieu Stoll, Frederic Allemand. Emosis, Illkirch-Graffenstaden, France


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


402

EVIDENCE OF ENDOTHELIAL ACTIVATION INDUCED BY LEUKEMIC BLASTS IN A COCULTURE SYSTEM
Paul Tieu1, 2, Ivan Stevic3, Davide Matino1, 2, 4, Anthony K. C. Chan1, 2, 5. 1Thrombosis a Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada. 2Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. 3Department of Pathology and Laboratory Medicine, London Health Sciences Centre and St. Joseph's Healthcare London, Western University, London, ON, Canada. 4Department of Medicine, McMaster University, Hamilton, ON, Canada. 5Department of Pediatrics, McMaster University, Hamilton, ON, Canada


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


403

THE RELEVANCE OF THROMBOINFLAMMATORY BIOMARKERS AND THEIR RELATIONSHIP WITH CIRCULATING GLYCOSAMINOGLYCANS IN END-STAGE RENAL DISEASE PATIENTS
Maddie Allen, Vinod Bansal, Fakiha Siddiqui, Debra Hoppensteadt, Emily Krupa, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


404

QUANTITATIVE TISSUE FACTOR PATHWAY INHIBITORANTIGEN RELEASE AND FUNCTIONALITY AFTER INTRAVENOUS ADMINISTRATION OF HEPARINS SOURCED FROM VARIOUS SPECIES IN NON-HUMAN PRIMATES
Mark Jaradeh, Baig Nausheen, Ahmed Kouta, Rick Duff, Lee Cera, Walter Jeske, Debra Hoppensteadt, Jawed Fareed. Department of Molecular Pharmacology a Neuroscience, Loyola University Medical Center, Maywood, IL, USA


405

INVESTIGATING THE ROLE OF IGM IN THE IMMUNE RESPONSE TO FACTOR VIII
Elizabeth S York1, 2, Glaivy Batsuli1, 2, Jasmine Ito1, 2. 1Aflac Cancer and Blood Disorders Center of Children, Atlanta, GA, USA. 2Emory University School of Medicine, Atlanta, GA, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


406

EPTACOG BETA EFFICACY AT 24 HOURS POST-INFUSION FOR MILD OR MODERATE BLEEDS IN INDIVIDUALS WITH HEMOPHILIA A OR B AND INHIBITORS
Lisa Boggio1, Maria Elisa Mancuso2, Suchitra Acharya3, Santiago Bonanad4, Meera Chitlur5, Yesim Dargaud6, Osman Khan7, Philip Maes8, Wolfgang Miesbach9, Danielle Nance10, Amina Rafique11, Daniel Bonzo12, Christopher Macie13, Thomas Wilkinson14, Miguel Escobar15. 1Rush University Medical Center, Chicago, IL, USA. 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. 3Northwell Health, New Hyde Park, NY, USA. 4University and Polytechnic Hospital La Fe, Valencia, Spain. 5Central Michigan University College of Medicine, Detroit, MI, USA. 6Lyon University Hospitals, Lyon, France. 7University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 8Antwerp University Hospital, Egedem, Belgium. 9Goethe University Hospital, Frankfurt, Germany. 10Banner MD Anderson Cancer Center, Phoenix, AZ, USA. 11Tulane University School of Medicine, New Orleans, LA, USA. 12LFB-USA, Inc, Framingham, MA, USA. 13HEMA Biologics, LLC, Louisville, KY, USA. 14GLOVAL LLC, Broomfield, CO, USA. 15University of Texas Health Science Center at Houston, Houston, TX, USA


407

IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Miguel Escobar1, Neha Agrawal2, Sagnik Chatterjee2, Swastik Bhattacharya2, Jorge Caicedo3, Michael Bullano3, Robert G Schultz3. 1The University of Texas Health Science Center, Houston, TX, USA. 2Complete HEOR Solutions, New Wales, PA, USA. 3Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA


408

A COMPARATIVE STUDY OF DIFFERENT METHODS OF HANDLING MISSING DATA IN PATIENT REPORTED OUTCOMES, BURDENS AND EXPERIENCES (PROBE) SCORE ALGORITHM AMONG PEOPLE WITH HEMOPHILIA
Quazi Ibrahim1, Alfonso Iorio1, 2, Randall Curtis3, Michael B. Nichol4, Declan Noone5, Jeffrey S. Stonebraker6, Mark W. Skinner1, 7, Federico Germini1, The PROBE Investigators8. 1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. 2Department of Medicine, McMaster University, Hamilton, ON, Canada. 3Factor VIII Computing, Berkeley, CA, USA. 4Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA. 5Irish Haemophilia Society, Dublin, Ireland. 6Poole College of Management, North Carolina State University, Raleigh, NC, USA. 7Institute for Policy Advancement Ltd, Washington, DC, USA. 8Patient Outcomes Research Group Ltd, New York, NY, USA


409

FACTOR VIII LEVEL COMPARISON IN PATIENTS WITH SEVERE HEMOPHILIA A ON EMICIZUMAB WITH INHIBITORS WITH ONE STAGE, BOVINE AND HUMAN CHROMOGENIC ASSAYS AND THE FACTOR VIII EQUIVALENCY OF EMICIZUMAB USING IN VIVO GLOBAL HEMOSTASIS ASSAYS
Hande Kizilocak1, Elizabeth Marquez-Casas1, Joshua Brown2, Jemily Malvar3, Guy Young1, 4. 1Children's Hospital Los Angeles, Hemostasis and Thrombosis Center, Los Angeles, CA, USA. 2Children, Los Angeles, CA, USA. 3Children, Los Angeles, CA, USA. 4University of California, Keck School of Medicine, Los Angeles, CA, USA


410

UPDATE ON AN ONGOING NIH-SPONSORED MULTICENTER RANDOMIZED TRIAL EVALUATING ILIAC VEIN STENT PLACEMENT IN PATIENTS WITH POST-THROMBOTIC SYNDROME AFTER DEEP VEIN THROMBOSIS
Suresh Vedantham1, Sameer Parpia2, Akhilesh Sista3, Ido Weinberg4, Elizabeth Magnuson5, David Cohen6, Mahmood Razavi7, Suman Wasan8, Anthony Comerota9, Susan Kahn10. 1Washington University in St. Louis, St. Louis, MO, USA. 2McMaster University, Hamilton, Canada. 3New York University, New York City, NY, USA. 4Harvard University, Boston, MA, USA. 5University of Missouri, Kansas City, MO, USA. 6Cardiovascular Research Foundation, New York City, NY, USA. 7St. Joseph's Hospital, Orange, CA, USA. 8UNC Health Care, Raleigh, NC, USA. 9Inova Heart and Vascular Institute, Alexandria, VA, USA. 10McGill University, Montreal, Canada


411

RISK MITIGATION DURING CONCIZUMAB PROPHYLAXIS IN PHASE 3 CLINICAL TRIALS IN PATIENTS WITH HEMOPHILIA A/B WITH AND WITHOUT INHIBITORS: MANAGEMENT OF BREAKTHROUGH BLEEDS AND DOSE OPTIMIZATION
Allison P Wheeler1, Amy Shapiro2, Thomas Porstmann3, Vlady Ostrow4, Hermann Eichler5, Jan Astermark6. 1Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. 2Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. 3Biopharm Medical Affairs Haemophilia, Novo Nordisk A/S, Zurich, Switzerland. 4Biopharmaceuticals, Novo Nordisk Inc, Plainsboro, NJ, USA. 5Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg-Saar, Germany. 6Center for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Malmo, Sweden


412

EFFECTS OF PLASMA-DERIVED FACTOR X CONCENTRATE ON PT AND APTT WHEN MEASURED IN A LOCAL OR CENTRAL LABORATORY IN PATIENTS UNDERGOING SURGICAL PROCEDURES
Eric Wolford1, Miranda Norton2. 1Bio Products Laboratory, Durham, NC, USA. 2Bio Products Laboratory, Elstree, United Kingdom


A7. PATHOPHYSIOLOGY OF THROMBOSIS


413

ELEVATED FACTOR VIII AND VON WILLEBRAND FACTOR ACTIVITY LEVELS IN PATIENTS WITH A HISTORY OF VTE AND CORTICOSTEROID USE.
J. Randle Adair, Ateefa Chaudhury. New Mexico Cancer Center, Albuquerque, NM, USA


A8. ANTITHROMBOTIC THERAPY


414

EXPERIENCE WITH UTILIZING A HEPARIN DOSING CALCULATOR TO ACHIEVE TARGET ACT GOALS IN CARDIAC ELECTROPHYSIOLOGY PROCEDURES
Anne E Rose1, Madeline Oie2, Marcus Mahnke3, Matthew M Kalscheur4, Joshua E Medow5. 1UW Health, Madison, WI, USA. 2University of Wisconsin School of Pharmacy, Madison, WI, USA. 3Integrated Vital Medical Dynamics, Madison, WI, USA. 4University of Wisconsin Department of Medicine, Madison, WI, USA. 5University of Wisconsin Department of Neurological Surgery, Madison, WI, USA


415

OPTIMIZING VENOUS THROMBOEMBOLISM PROPHYLAXIS AMONG PATIENTS RECEIVING SYSTEMIC THERAPY FOR LYMPHOMA: A ROOT-CAUSE ANALYSIS
Natasha S. Rupani1, Ronit Marcus1, Ruth Law2, Patricia Leung2, Charmaine Mothersil2, Zeinab Yusuf2, Eric Tseng2, Lisa Hicks2. 1Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Division of Hematology, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada


416

ANALYSIS OF THE SAFETY AND EFFICACY OF DIRECT-ACTING ORAL ANTICOAGULANTS FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN OBESITY
Jeffrey D Sperry, Anne E Rose. University of Wisconsin Health, Madison, WI, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


417

CHARACTERIZING BLOOD TRANSFUSION BURDEN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM A PATIENT CHART AUDIT SURVEY
David Dingli1, Jordan Messer2, Johan Mohd Sani3, Alex Sherman2, Ravi Sarode4. 1Mayo Clinic, Rochester, MN, USA. 2BioCryst Pharmaceuticals, Inc, Durham, NC, USA. 3KJT Group, Rochester, NY, USA. 4University of Texas Southwestern Medical Center, Dallas, TX, USA


418

VALIDATION OF A NEW KIT FOR THE DETERMINATION OF FACTOR IX ACTIVITY
Tara Quinton, John Fraser, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc, Dartmouth, NS, Canada

10:00 - 11:00 AM
SHORT TALKS
SHORT TALKS - BLEEDING II
Chair/Organizer: Robert Sidonio, Yasmina Abajas
Sheraton Ballroom I-III


10:00

A LIBRARY OF SIRNA LIPID NANOPARTICLES THAT KNOCKDOWN SPECIFIC PRO- AND ANTI-FIBRINOLYTIC PROTEINS IN ANIMAL MODELS OF THROMBOSIS AND BLEEDING.
Francesca Ferraresso1, Lih Jiin Juang1, Amy Strilchuk1, Christian Kastrup2, 3. 1Michael Smith Laboratories and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada. 2Blood Research Institute, Versiti, Milwaukee, WI, USA. 3Departments of Surgery, Biochemistry, Biomedical Engineering, and Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA


10:12

TITLE: MICE WITH FACTOR VIII DEFICIENCY SHOW FEATURES OF PAIN IN HEMOPHILIA
Raghda Fouda1, Natalie Garcia1, Stacy Kiven 1, Kalpna Gupta1, 2. 1Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA. 2Southern California Institute for Research and Education, VA Medical Center, Long Beach, CA, USA


10:24

PROTEOSTASIS REGULATORS IMPROVE PROTEIN SECRETION AND ACTIVITY OF FVIII MISSENSE MUTANTS.
Vishal Srivastava1, Wei Wei1, Zhigang Liu1, Zhang Yuan1, Tingwei Mu2, Zhang Bin1. 1Genomic Medicine Institute, Lerner Research Institute of Cleveland Clinic Cleveland, OH, USA. 2Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, USA


10:36

THE FREQUENCY AND SIGNIFICANCE OF CROSS-REACTING ANTI-PORCINE FVIII INHIBITORS IN PATIENTS WITH CONGENITAL AND ACQUIRED HEMOPHILIA A
Maddie S Stephen1, Carolyne Elbaz2, Hina Hanif3, Russell Ombao3, Jenny Gan3, Katerina Pavenski2, 3, Jerry Teitel2, Michelle Sholzberg2, 3. 1University of Toronto Department of Medicine, Toronto, ON, Canada. 2Department of Medicine Division of Hematology/Oncology St. Michael's Hospital, Toronto, ON, Canada. 3Department of Laboratory Medicine and Pathology, St. Michael's Hospital, Toronto, ON, Canada


10:48

HEREDITARY HEMORRHAGIC TELANGIECTASIA IS ASSOCIATED WITH A HIGHER PREVALENCE OF HEAVY MENSTRUAL BLEEDING.
Kimberley/ M Youkhana1, Tamy/ H Moraes Tsujimoto2, Feng-Chang Lin2, Kristy Pahl3, Andra James 4, Nicole Schaefer5, Marianne/ S Clancy5, Raj/S Kasthuri1. 1University of North Carolina, Chapel Hill, Chapel Hill, NC, USA. 2Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. 33Division of Pediatric Hematology/Oncology, Duke University, Durham, NC, USA. 4Department of Obstetrics and Gynecology, Duke University Durham, NC, USA. 5Cure HHT Foundation, Monkton, MD, USA


SHORT TALKS - PLATELETS AND VESSELS
Chair/Organizer: Peter Kouides, Brett Grieb
Chicago Ballroom VII


10:00

SICKLE RED BLOOD CELL DERIVED EXTRACELLULAR VESICLES ACTIVATE ENDOTHELIAL CELLS AND ENHANCE SICKLE RED CELL ADHESION MEDIATED BY VON WILLEBRAND FACTOR
Ran An1, Yuncheng Man1, Kevin Cheng1, Tianyi Zhang2, Chunsheng Chen3, Erdem Kucukal1, William Wulftange4, Utku Goreke1, Allison Bode1, 5, Lalitha Nayak5, Gregory Vercellotti3, John Belcher3, Jane Little6, Umut Gurkan1, 3, 7. 1Mechanical and Aerospace Engineering Department, Case Western Reserve University, Cleveland, OH, USA. 2Physiology and Biophysics Department, Case Western Reserve University, Cleveland, OH, USA. 3Division of Hematology, Oncology and Transplantation, Vascular Biology Center, University of Minnesota, Minneapolis, MN, USA. 4Biomedical Engineering Department, Case Western Reserve University, Cleveland, OH, USA. 5Department of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 6Division of Hematology a UNC Blood Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 7Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA


10:12

ACQUIRED PLATELET STORAGE POOL DISORDERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Brett Grieb, Rajiv K Pruthi, Dong Chen, Meera Sridharan. Mayo Clinic Rochester, Rochester, MN, USA


10:24

SARS-COV-2 RBD AND ITS VARIANTS CAN INDUCE PLATELET ACTIVATION AND CLEARANCE: IMPLICATIONS FOR VACCINATIONS AND ANTIBODY THERAPY AGAINST COVID-19
Xiaoying Ma1, 2, Jady Liang2, 3, Guangheng Zhu2, 4, Preeti Bhoria2, 4, Daniel T MacKeigan2-5, Lisha Lin1, 2, Ziyan Chen1, 2, 4, 6, Zhenze Liu2, Chuanbin Shen1, 2, Yuchong Li2, 7, Hamed Shaykhalishahi2, 4, Jiamin Zhang1, 2, Pingguo Chen1, 2, Haibo Zhang2, 3, 5, 7, 8, Ori Rotstein2, 5, Heyu Ni1-6. 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2Keenan Research Centre for Biomedical Science of St. Michael, Toronto, ON, Canada. 3Department of Physiology, University of Toronto, Toronto, ON, Canada. 4Toronto Platelet Immunobiology Group, Toronto, ON, Canada. 5Department of Medicine, University of Toronto, Toronto, ON, Canada. 6Canadian Blood Services, Ottawa, ON, Canada. 7The State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 8Department of Anesthesiology and Pain Medicine and Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada


10:36

HMGB1 MEDIATES INCREASED P2Y12 LOCALIZATION AT THE PLATELET SURFACE IN SICKLE CELL DISEASE
Deirdre Nolfi-Donegan1, 3, Gowtham Annarapu3, Lisa Maurer1, Cheryl Hillery1, Sruti Shiva2, 3. 1Department of Pediatrics, Division of Hematology/Oncology, Children, PITTSBURGH, PA, USA. 2Department of Pharmacology a Chemical Biology, University of Pittsburgh, PITTSBURGH, PA, USA. 3Heart, Lung, Blood Vascular Medicine Institute, University of Pittsburgh, PITTSBURGH, PA, USA


10:48

PERSEVERING ENDOTHELIAL CELL ACTIVATION AND HYPERCOAGULABILITY AFTER COVID-19 RECOVERY. THE PROSPECTIVE ROADMAP-POSTCOVID-19 STUDY.
Patrick Van Dreden1, 4, Meletios A. Dimopoulos2, Aurelie Rousseau1, Ismail Elalamy3, Grigorios Gerotziafas3, 4. 1Clinical Research Stago, Gennevilliers, France. 2University of Athens School of Medecine, Athens, Greece. 3APHP Hopital Tenon, Paris, France. 4INSERM U938, Paris, France


SHORT TALKS - THROMBOSIS CLINICAL AND SCIENCE
Chair/Organizer: Katrien Devreese, Shreya Agarwal
Sheraton Ballroom IV-V


10:00

EXPLORING THE RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN CHILDREN WITH SICKLE CELL DISEASE
Shreya Agarwal 1, 2, Kayla Foster 1, 2 , Shaniqua Johnson 1, 2 , Mary Shapiro 1, 2 , HyoJyeong Han1, 2 , Michael E. Scheurer 2, 3 , Gladstone Airewele 1, 2, Sarah E. Sartain 1, 2. 1Texas Children's Hospital, Division of Pediatric Hematology-Oncology, Houston, TX, USA. 2Baylor College of Medicine, Houston, TX, USA. 3Texas Children's Hospital, Center for Epidemiology and Population Health, Houston, TX, USA


10:12

FINDING THE GAP IN PEDIATRIC POST-THROMBOTIC SYNDROME
Denise Bastas, Leonardo Brandao, Jennifer Vincelli, Nour Amiri, Karem Abdul-Samad, Samantha Stephens, Laura Avila . The Hospital for Sick Children, Toronto, ON, Canada


10:24

CHARACTERIZING A PHYSIOLOGICALLY RELEVANTIN-VITROTHROMBOLYSIS MODEL UTILIZING FLUORESCENTLY LABELED CLOTS FORMED UNDER SHEAR
Alexei Christodoulides1, Ziqian Zeng2, Nathan J Alves1, 2. 1Indiana University School of Medicine - Department of Emergency Medicine, Indianapolis, IN, USA. 2Purdue University - Department of Biomedical Engineering, West Lafayette, IN, USA


10:36

IN VIVO MURINE STUDIES DEMONSTRATE THAT NEUTROPHIL ACTIVATION BY ANTI-NAP2 ANTIBODIES CONTRIBUTES TO VACCINE-INDUCED IMMUNE THROMBOCYTOPENIA AND THROMBOSIS (VITT)
Conroy O Field1, 2, Hyunjun Kim1, M. Anna Kowalska1, 7, Matthew D Weitzman3, 4, Gowthami Arepally6, Douglas B Cines3, Lubica Rauova1, 5, Mortimer Poncz1, 5. 1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2Pharmacology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA. 3Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 4Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 6Division of Hematology, Duke University Medical Center, Durham, NC, USA. 7Institute of Medical Biology, Polish Academy of Science, Lodz, Poland

11:05 - 12:20 PM
PLENARY SESSION
DIVERSITY, EQUITY, AND INCLUSION
Chair/Organizer: Cathy Hayward, Robert Sidonio
Sheraton Ballroom IV-V


INTRODUCTION VIDEO.


11:05

PROMOTING EQUITY AND DIVERSITY IN ACADEMIC AND CLINICAL PRACTICE
Sonia Anand. McMaster University


11:25

COMBATING SEXISM IN DIAGNOSING AND MANAGING BLEEDING DISORDERS
Angela Weyand. University of Michigan Medical School


11:45

ADDRESSING BARRIERS IN PATIENT CARE: A PANEL DISCUSSION
Sara Vazquez. University of Utah Health


12:05

Q&A.

12:35 - 1:35 PM
SATELLITE SYMPOSIUM
GENE THERAPY ELIGIBILITY: DELINEATING DIFFERENCES FROM CLINICAL TRIAL TO CLINICAL PRACTICE (SPONSORED BY CSL BEHRING MEDICAL AFFAIRS)
Chicago Ballroom IX-X

Join us and engage in a robust dialogue covering clinical and psychosocial considerations for gene therapy. This panel discussion, led by speakers from multidisciplinary teams will address topics such as: 1) Determining patient eligibility, insights from clinical trial to apply to clinical practice 2) Addressing liver health considerations and evaluation for referrals to a partnering hepatologist 3) Assessing eligibility based on lifestyle screening, patient expectations and commitment of therapy MODERATOR: Michael Recht, MD, PhD, MBA is the Chief Science Officer, American Thrombosis and Hemostasis Network; Professor of Clinical Pediatrics at Yale University School of Medicine SPEAKER PANEL includes: Sabrina Farina, LMSW at UT Health Houston; Mark Reding, MD a Professor of Medicine & Center for Bleeding and Clotting Disorders Director at the University of Minnesota Medical Center and Bruce Luxon, MD, PhD who is a Chair of the Department of Medicine Chief of Service for the Department of Medicine at Georgetown University Hospital



PROPHYLAXIS IN PATIENTS WITH VON WILLEBRAND DISEASE: EXPERT PERSPECTIVES AND SHARED EXPERIENCES - (ORGANIZED BY MEDICOM WORLDWIDE, INC AND IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA PHARMACEUTICALS U. S. A, INC. )
Chair/Organizer: Robert Sidonio, Jr
Chicago Ballroom VI

We invite you to join us for a dynamic and interactive panel discussion focused on new advances in prophylaxis treatment for von Willebrand Disease (VWD) and data supporting emerging therapeutic strategies. Our panel will spend time addressing guidelines, treatment strategies, and patient management considerations. Come prepared with your questions for an engaging discussion. Pre-registration is required for this event.


1:50 - 3:20 PM
THROMBOSIS
MANAGEMENT OF UNUSUAL SITE THROMBOSIS ACROSS THE AGE SPECTRUM
Chair/Organizer: Julie Jaffray, Anne Rose
Sheraton Ballroom IV-V


1:50

SPLANCHNIC VEIN THROMBOSIS
Anita Rajasekhar. University of Florida


2:15

CEREBRAL SINUS VENOUS THROMBOSIS (CSVT) DIAGNOSIS AND TREATMENT
Thalia Field. University of British Columbia


2:40

SHARED DECISION MAKING WHEN THERE IS LIMITED EVIDENCE
Stephan Moll. University of North Carolina School of Medicine


3:05

Q&A.

1:50 - 3:20 PM
HEMOSTASIS
NEW THERAPIES FOR BLEEDING DISORDERS
Chair/Organizer: Robert Sidonio, Michael Recht
Sheraton Ballroom I-III


INTRODUCTION VIDEO.


1:50

EMICIZUMAB IN THE HIGH ACHIEVING ATHLETE
Meera Chitlur. Central Michigan University/Children's Hospital of Michigan


2:15

NEW AGENTS: BIV-001 AND REBALANCING AGENTS
Mark Reding. University of Minnesota


2:40

NEW THERAPIES FOR BLEEDING OTHER THAN HEMOPHILIA
Ayesha Zia. University of Texas Southwestern, Dallas, TX


3:05

Q&A.

1:50 - 3:20 PM
LABORATORY / BASIC SCIENCE
PATHOGENESIS AND LABORATORY DIAGNOSIS OF PLATELET PROTHROMBOTIC STATES
Chair/Organizer: Cathy Hayward, Peter Kouides
Chicago Ballroom VII


1:50

PLATELET MECHANICS AND BLEEDING PHENOTYPE
Oluwamayokun Oshinowo. Georgia Institute of Technology/Emory University


2:15

PATHOGENESIS OF PLATELET PROTHROMBOTIC STATES (HITT/VITT)
Donnie Arnold. McMaster University


2:40

OVERVIEW OF LABORATORY DIAGNOSTIC TESTING ASSAYS FOR HITT VS VITT
Anand Padmanabhan.


3:05

Q&A.

3:20 - 4:05 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


501

VALIDATION OF BIVALIRUDIN CONCENTRATION ASSAY AND COMPARISON TO APTT RATIO
Melissa Stuart, Julie Tange, Dong Chen, M. D, Ph. D, Rajiv Pruthi, MBBS. Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


502

FORTE: AN OBSERVATIONAL STUDY OF FOSTAMATINIB AS SECOND LINE THERAPY IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN REAL-WORLD CLINICAL PRACTICE
Ruchika Goel1, Aaron Sheppard2, Ryan Flynn2, David Hughes3. 1Department of Medicine, Southern Illinois University School of Medicine, Springfield, IL, USA. 2Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA. 33Department of Pharmacy, Boston Medical Center, Boston, MA, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


504

CLEARANCE OF GIROCTOCOGENE FITELPARVOVEC VECTOR DNA IN ADULTS WITH SEVERE HEMOPHILIA A
Patrick F. Fogarty1, Brinda K. Tammara1, Justin Smith2, Delphine Agathon3, Florence Ganne3, Frank Plonski1, Jeremy Rupon1. 1Pfizer Inc, Collegeville, NY, USA. 2Pfizer Inc, Groton, CT, USA. 3Pfizer Inc, Paris, France


505

EVALUATION OF ADAMTS13 LEVELS IN A PLASMA-DERIVED FVIII CONCENTRATE: TARGET ON CTTP TREATMENT
Filippo Mori1, Ilaria Nardini1, Silvia Nannizzi1, Prasad Mathew1, Alessandro Gringeri1, Erin Weigel2. 1Medical and Scientific Affairs, Kedrion Biopharma, Lucca, Italy. 2U. S Medical Affairs Kedrion Biopharma, Fort Lee, NJ, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


506

ALFA PROTECT: A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED CHILDREN AGED 7-
Jonathan Ducore1, Monika Mass Enriquez2, Claudia Tueckmantel2, Mindy Simpson3, Sanjay Ahuja4. 1Hemostasis and thrombosis Center, UC Davis Medical Center, Sacramento, CA, USA. 2Bayer AG, Wuppertal, Germany. 3Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA. 4UH Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA


507

PREVALENCE AND DETERMINANTS OF FACTEUR VIII INHIBITORS IN A COHORT OF 30 PATIENTS AT THE UNIVERSITY TEACHING HOSPITAL OF YOPOUGON IN IVORY COAST
mahi C E Gnemagnon1, eusebe A Adjambri1, 2, N'Golo Meite2, mahou sangare1, 2, Mireil Yayo-Aye1, 2, edjeme M F Meledje1, 2, duni sawadogo1, 2, ibrahima sanogo1, 2. 1university teaching hospital, Bouake, Cote d Ivoire. 2UFHB, abidjan, Cote d Ivoire. 3UFHB, abidjan, Cote d Ivoire. 4UFHB, abidjan, Cote d Ivoire. 5UFHB, abidjan, Cote d Ivoire. 6UFHB, abidjan, Cote d Ivoire. 7UFHB, abidjan, Cote d Ivoire. 8UFHB, abidjan, Cote d Ivoire


508

MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B
Esteban Gomez1, Adam Giermasz2, Giancarlo Castaman3, Nigel S. Key4, Susan Lattimore5, Frank W. G. Leebeek6, Wolfgang A. Miesbach7, Michael Recht5, Annette von Drygalski8, David Cooper9, 10, Yanyan Li11, Blanca Salazar11, Steven W. Pipe12. 1Phoenix Children's Hospital, Phoenix, AZ, USA. 2University of California Davis, Sacramento, CA, USA. 3Azienda Ospedaliera Universitaria Careggi, Florence, Italy. 4University of North Carolina, Chapel Hill, NC, USA. 5Oregon Health a Science University, Portland, OR, USA. 6Erasmus University Medical Center, Rotterdam, Netherlands. 7University Hospital Frankfurt, Frankfurt, Germany. 8University of California San Diego, La Jolla, CA, USA. 9uniQure BV, Amsterdam, Netherlands. 10uniQure Inc, Lexington, MA, USA. 11CSL Behring, King of Prussia, PA, USA. 12University of Michigan, Ann Arbor, MI, USA


509

LABORATORY VALIDATION OF SEROTONIN RELEASE ASSAY BY LIQUID MASS SPECTROMETRY
Rachel R Leger, Ravinder J Singh, Ph. D. , Jansen N Seheult, M. B, B. Ch, M. D. , Nahla M Heikal, M. D. , Rajiv K Pruthi, M. B. B. S. Mayo Clinic, Rochester, MN, USA


510

COAGADEX IN THE PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HEREDITARY FACTOR X DEFICIENCY UNDERGOING MAJOR SURGERY
Miranda Norton1, Eric Wolford2. 1Bio Products Laboratory, Elstree, United Kingdom. 2Bio Products Laboratory, Durham, NC, USA


511

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AND CHRONIC PAIN IN PATIENTS WITH HAEMOPHILIA A AND B BY USING AN ELECTRONIC MOBILE APP - RESULTS OF THE EMIQOL STUDY
Sylvia von Mackensen1, David Schmoldt2, Andreas Rosch2, Ronald Fischer3, Katharina Holstein4, Susan Halimeh5, Wolfgang Mondorf6, EmiQoL Group . 1University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 2smart medication eHealth Solutions GmbH, Frankfurt, Germany. 3SRH Haemophilia Treatment Centre, SRH Kurpfalz-Hospital Heidelberg, Heidelberg, Germany. 4II. Medical Department, Haemophilia Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 5Coagulation Centre Rhine-Ruhr, Duisburg, Germany. 6Haemostas-Frankfurt, Frankfurt, Germany


512

IMPROVED QUALITY OF LIFE AND SATISFACTION WITH N8-GP IN US PATIENTS
Allison P Wheeler1, Roshni Kulkarni2, Adam R Wufsus3, Vlady Ostrow3, Miguel Escobar4. 1Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA. 2Michigan State University, East Lansing, MI, USA. 3Novo Nordisk Inc, Plainsboro, NJ, USA. 4University of Texas Health Science Center, Houston, TX, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


513

VENOUS THROMBOEMBOLISM IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW
Jermie Gandhi1, Keith Mages2, Kimberley Chien1, Nicole Kucine1. 1Weill Cornell Medicine, New York, NY, USA. 2University at Buffalo, Buffalo, NY, USA


A8. ANTITHROMBOTIC THERAPY


514

INCREASED D-DIMER NORMALIZATION AND REDUCED INCIDENCE OF THROMBOSIS IN PEGCETACOPLAN-TREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: WEEK 48 INTERIM RESULTS FROM THE 307 LONG-TERM EXTENSION STUDY
David Dingli1, Michael Yeh2, Mohammed Al-Adhami2, Jinny Min2, Jessica Savage2, Ilene Weitz3. 1Mayo Clinic, Rochester, MN, USA. 2Apellis Pharmaceuticals, Inc, Waltham, MA, USA. 3Keck-USC School of Medicine, Los Angeles, CA, USA


515

DIFFERENTIAL NEUTRALIZATION OF UNFRACTIONATED HEPARIN AND ENOXAPARIN BY ANDEXANET ALFA.
Joseph Lewis, Omer Iqbal, Walter Jeske, Debra Hoppensteadt, Fakiha Siddiqui, Jawed Fareed, Guy Olson. Loyola University Medical Center, Maywood, IL, USA


516

EVALUATING CHROMOGENIC AND CLOT-BASED DRUG CONCENTRATION ASSAYS FOR BIVALIRUDIN MONITORING
Prashant Raghavendran, Alexandra Borst, Benjamin Tillman, Allison Wheeler, David Gailani. Vanderbilt University Medical Center, Nashville, TN, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


503

COLLABORATION FOR THE LONG-TERM FOLLOW-UP OF PEOPLE WITH HEMOPHILIA TREATED WITH GENE THERAPY: WORLD FEDERATION OF HEMOPHILIA - AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK
Donna Coffin1, Barbara Konkle1, 2, Mayss Naccache1, Cary Clark3, Lindsey George4, Alfonso Iorio5, Wolfgang Miesbach6, Declan Noone7, Flora Peyvandi8, Steve Pipe9, Michael Recht10, Mark Skinner11, Leonard A. Valentino12, Johnny N. Mahlangu13, Glenn Pierce1. 1World Federation of Hemophilia, montreal, QC, Canada. 2University of Washington, Seattle, WA, USA. 3International Society on Thrombosis and Haemostasis, Carrboro, NC, USA. 4The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5McMaster University, Hamilton, ON, Canada. 6University Hospital Frankfurt, Frankfurt, Germany. 7European Haemophilia Consortium, Brussels, Belgium. 88Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy. 9University of Michigan, Ann Arbor, MI, USA. 10American Thrombosis and Hemostasis Network, Rochester United States. 11Institute for Policy Advancement Ltd, Washington, WA, USA. 12National Haemophilia Foundation, New York, NY, USA. 13University of the Witwatersrand, Johannesburg, South Africa


517

DIRECT ORAL ANTICOAGULANTS AFTER BARIATRIC SURGERY: A QUALITY IMPROVEMENT PROJECT
Julia A Bayadinova1, Laurie A. Sardo1, 2, Siraj Mithoowani1, 2. 1St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada. 2McMaster University, Hamilton, ON, Canada


518

OUTCOMES ASSOCIATED WITH ISOLATED DISTAL DEEP VEIN THROMBOSIS: A COMPARATIVE ANALYSIS OF ANTICOAGULATION VERSUS SERIAL ULTRASOUND MONITORING
Tuyet Lien D. Lam1, Alex Brewster1, Stacy A. Johnson2, Aubrey E. Jones1, 3, Sara R. Vasquez1, 3, Daniel Witt1, 3. 1University of Utah College of Pharmacy, Salt Lake City, UT, USA. 2University of Utah School of Medicine, Salt Lake City, UT, USA. 3Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA

4:05 - 5:35 PM
THROMBOSIS / HEMOSTASIS
HEALTH AND WELLNESS IN HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Lena Volland, Michael Recht
Sheraton Ballroom I-III


INTRODUCTION VIDEO.


4:05

THE PSYCHOLOGICAL IMPACT OF PULMONARY EMBOLISM
Rachel Rosovsky. Massachusetts General Hospital and Harvard Medical School


4:30

THE PSYCHOLOGICAL IMPACT OF PAIN IN HEMOPHILIA
Lena Volland. National Hemophilia Foundation


4:55

THE PSYCHOLOGICAL IMPACT OF THROMBOSIS IN ATHLETES
Julie Partridge. Southern Illinois University Carbondale


5:20

Q&A.

4:05 - 5:35 PM
LABORATORY
IMPROVING THROMBOPHILIA AND BLEEDING DISORDER INVESTIGATIONS
Chair/Organizer: Karen Moser, Marian Rollins-Raval
Chicago Ballroom VII


INTRODUCTION VIDEO.


4:05

CONTRIBUTIONS OF BETSY VANCOTT TO THROMBOSIS LABORATORY MEDICINE
Catherine Hayward. McMaster University


4:30

IMPROVING DIAGNOSIS OF RARE BLEEDING DISORDERS
Rajiv Pruthi. Mayo Clinic


4:55

TOP 5 VISUAL DESIGN TIPS FOR TEACHING COAGULATION
Evelyn Lockhart. University of New Mexico Health Science Center


5:20

Q&A.

4:05 - 5:35 PM
BASIC SCIENCE
NOVEL HEMOSTASIS MECHANISMS
Chair/Organizer: Meera Chitlur, Bhavya Doshi
Sheraton Ballroom IV-V


4:05

NOVEL PLATELET MIMETICS FOR HEMOSTASIS
Anirban Sen Gupta. Case Western Reserve University


4:30

HYPERACTIVE GENE VARIANTS FOR HEMOPHILIA THERAPY
Ben Samelson-Jones. The Children's Hospital of Philadelphia


4:55

BREAKING THE FIBRINOLYTIC SPEED LIMIT WITH MAGNETICALLY POWERED MICROBOTS
Keith Neeves. University of Colorado Denver | Anschutz Medical Campus


5:20

Q&A.

5:35 - 6:20 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB




604

CLINICAL DEVELOPMENT OF EFANESOCTOCOG ALFA (BIVV001), A NEW CLASS OF FACTOR VIII (FVIII) REPLACEMENT THERAPY DESIGNED TO PROVIDE HIGH SUSTAINED FACTOR ACTIVITY.


A1. ANTICOAGULATION CLINICS


601

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) VS STANDARD OF CARE (SOC) IN CANCER PATIENTS WITH CATHETER ASSOCIATED VENOUS THROMBOEMBOLISM.
Monika Kulasekaran1, Hira Latif2, Ravi Anandakrishnan1, Sandrine Niyongere3, Arshdeep Brar4. 1MedStar Health, Baltimore, MD, USA. 2MedStar Washington Hospital center, Washington, DC, USA. 3University of Maryland, Baltimore, MD, USA. 4Anne Arundel Medical Center, Annapolis, MD, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


602

OXIDATIVE STRESS BIOMARKERS AND THEIR RELEVANCE TO FATTY ACID-BINDING PROTEIN (FABP) IN STAGE FIVE CHRONIC KIDNEY DISEASE ON HEMODIALYSIS (CKD5-HD).
Divya Sridharan, Pranathi Karumanchi, Debra Hoppensteadt, Emily Bontekoe, Jawed Fareed, Guy Olson. Loyola University Medical Center, Maywood, IL, USA


603

CLINICAL OUTCOMES IN PATIENTS WITH SEVERE ADAMTS13 DEFICIENCY ACROSS US HOSPITALS
Shan Xing1, Michael Bullano1, Tasneem Lokhandwala2, Sharanya Murty2, Sarah Hale1. 1Takeda Development Center Americas, Inc, Lexington, MA, USA. 2Xcenda LLC, Carrollton, TX, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


605

EVALUATION OF A NEW CHROMOGENIC FACTOR IX ASSAY KIT
Julie I. Tange, Nahla Heikal, Dong Chen, Rajiv K. Pruthi. Comprehensive Hemophilia Center and Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


606

ATHN 16: SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW FOR THE TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORSWITH OR WITHOUT PROPHYLACTIC TREATMENT
TAMMUELLA CHRISENTERY-SINGLETON1, W. ALLAN ALEXANDER2, AHMAD AL-SABBAGH3, DANIEL BONZO3, MICHAEL U. CALLAGHAN4, MIGUEL ESCOBAR5, ADAM GIERMASZ6, M. NIKKI HIRSH7, JANNA JOURNEYCAKE8, SONIA NASR9, DORIS V. QUON10, MARK REDING11, MICHAEL RECHT7, 12. 1Louisiana Center for Advanced Medicine, Slidell, LA, USA. 2Aoede Associates, Louisville, KY, USA. 3LFB-USA, Inc, Framingham, MA, USA. 44Central Michigan University, Detroit, MI, USA. 5University of Texas Health Science Center, Houston, TX, USA. 6University of California, Davis, Sacramento, CA, USA. 7American Thrombosis and Hemostasis Network, Rochester, NY, USA. 8Oklahoma Center for Bleeding and Clotting Disorders at OU Health, Oklahoma City, OK, USA. 9GLOVAL LLC, Broomfield, CO, USA. 10Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. 11University of Minnesota, Minneapolis, MN, USA. 12Oregon Health a Science University, Portland, OR, USA


607

A COMPARISON STUDY BETWEEN THE CLOT SOLUBILITY TEST AND A QUANTITATIVE FXIII ACTIVITY ASSAY IN THE EVALUATION OF SCREENING FOR FXIII DEFICIENCY.
Natasha S. Rupani1, Shunyan Lu2, Elena Brnjac2, Jacqueline Ongteco2, Rita Selby1, 2. 1Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada


608

A COMMUNITY EFFORT TO DEVELOP A NATIONAL RESEARCH BLUEPRINT FOR INHERITABLE BLEEDING DISORDERS
Maria E. Santaella1, Michelle L. Witkop1, Michael Recht2, Keri Norris1, Brett Spitale1, Esmeralda Vazquez1, Donna M. DiMichelle3, Kevin Mills1. 1National Hemophilia Foundation, New York, NY, USA. 2American Thrombosis and Hemostasis Network, Rochester, NY, USA. 3Donna DiMichele Consulting, LLC, Washington, DC, USA


609

EFFECTIVE USE OF HUMAN FIBRINOGEN CONCENTRATES FOR BLEEDING PROPHYLAXIS IN CHILDREN AND YOUNG ADULTS WITH CONGENITAL AFIBRINOGENEMIA.
Julia E Shuford1, 2, 3, Lynda Martinez4, Joseph S Stanco4, Suchitra S Acharya4, Robert F Sidonio1, 2, 3, Megan C Brown1, 2, 3. 1Emory University School of Medicine, Atlanta, GA, USA. 2Children's Healthcare of Atlanta, Atlanta, GA, USA. 3 Aflac Cancer a Blood Disorders Center, Atlanta, GA, USA. 4Cohen Children's Medical Center, New Hyde Park, NY, USA


610

HEMOSTATIC, INFLAMMATORY AND ENDOTHELIAL DYSREGULATION CONTRIBUTES TO THE HYPERCOAGULABLE STATE IN PULMONARY EMBOLISM PATIENTS
Fakiha Siddiqui1, Amir Darki1, Omer Iqbal1, Debra Hoppensteadt1, Bulent Kantarcioglu1, Alfonso Tafur2, Manuel Monreal3, Jawed Fareed1. 1Loyola University Medical Center, MAYWOOD, IL, USA. 2North Shore Health Systems, Evanston, IL, USA. 3Hospital Universitari Germans Trias i Pujol, Barcelona Spain


611

EFFICACY OF EPTACOG BETA IN THE 75G/KG INITIAL DOSE REGIMEN FOR THE TREATMENT OF JOINT AND NON-JOINT BLEEDS IN CHILDREN AND ADOLESCENTS WITH HEMOPHILIA A OR B AND INHIBITORS
Robert Sidonio, Jr. 1, Manual Carcao2, Yasmina Abajas3, Sanjay Ahuja4, Giancarlo Castaman5, Daniel Hart6, Cedric Hermans7, Johnny Mahlangu8, Lynn Malec9, Ulrike Nowak-Gottl10, Mindy Simpson11, Daniel Bonzo12, Christopher Macie13, Thomas Wilkinson14, Janna Journeycake15. 1Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA. 2The Hospital for Sick Children, Toronto, ON, Canada. 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4Rainbow Babies a Children's Hospital, Cleveland, OH, USA. 5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy. 6The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, QMUL, London, United Kingdom. 7Catholic University of Louvain, Hemophilia Center of the Saint-Luc University Hospital, Brussels, Belgium. 8University of the Witwatersrand, Johannesburg, South Africa. 9Medical College of Wisconsin, Milwaukee, WI, USA. 10University Medical Center Schleswig-Holstein, Kiel, Germany. 11Rush University Medical Center, Chicago, IL, USA. 12LFB-USA, Inc, Framingham, MA, USA. 13HEMA Biologics, LLC, Louisville, KY, USA. 14GLOVAL LLC, Broomfield, CO, USA. 15Oklahoma Bleeding and Clotting Disorders Center at OU Health, Oklahoma City, OK, USA


612

ACUTE DEEP VENOUS THROMBOSIS FOLLOWING SARS-COV-2 VACCINATION AS THE INITIAL PRESENTATION OF CONGENITAL FACTOR VII DEFICIENCY
Alyson E. Trillo1, 2, Joanna A. Davis1, Krysten Sargenton1, Fernando F. Corrales-Medina1. 1University of Miami-Miller School of Medicine, Miami, FL, USA. 2Holtz Children's Hospital, Miami, FL, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


613

IDENTIFICATION OF THE HUB GENES BY COALESCING MOLECULAR INTERACTOMES OF COVID-19 AND THROMBOSIS
Mushtaq Hussain1, Anusha Amanullah1, Nusrat Jabeen2, Bulent Kantarcioglu3, Fakiha Siddiqui3, Jawed Fareed3. 1Dow University of Health Sciences, Dow College of Biotechnology, Karachi Pakistan. 2University of Karachi, Department of Microbiology, Karachi Pakistan. 3Loyola University Medical Center, MAYWOOD, IL, USA


A8. ANTITHROMBOTIC THERAPY


614

TO LOAD OR NOT TO LOAD: SAFETY AND EFFICACY OF WARFARIN DOSING IN PEDIATRIC CARDIOTHORACIC SURGERY PATIENTS
Joshua W Branstetter1, Hania Zaki1, Madyson Allard1, Gary M Woods2, 3. 1Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA, USA. 2Department of Hematology and Oncology, Children's Healthcare of Atlanta, Atlanta, GA, USA. 3Department of Pediatrics, Emory University, Atlanta, GA, USA


615

ANTICOAGULANT, HIT ANTIBODY, AND PLATELET MODULATORY ACTIONS OF GLYCOSAMINOGLYCANS (GAG) FROM SEA CUCUMBERS
Emily Krupa, Ambar Farooqui, Debra Hoppensteadt, Joseph Lewis, Omer Iqbal, Walter Jeske, Jawed Fareed, Mark Jaradeh. Loyola University Medical Center, Maywood, IL, USA


616

EVALUATION OF A STANDARDIZED THROMBOPROPHYLAXIS PROTOCOL IN MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
Roma V. Rajput, Matthew Sharron, Padma Pavuluri, Hayley Hansen, Emily Ansusihna, Roberta L. DeBiasi, Suvankar Majumdar, Yaser Diab. Children's National Hospital, Washington, DC, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


617

A PILOT STUDY OF US HTC PHYSICAL THERAPISTS' KNOWLEDGE AND EDUCATIONAL NEEDS: ESTABLISHING THE FOUNDATION FOR A MENTORSHIP PROGRAM
Lena M Volland, Maria E Santaella, Neil Frick, Kate Nammacher, Cynthia Nichols, Michelle Witkop. National Hemophilia Foundation, New York City, NY, USA

6:20 - 7:35 PM
SATELLITE SYMPOSIUM
FOCUS ON FACTOR DINNER (SPONSORED BY SANOFI)
Chicago Ballroom IX-X

Treating hemophilia is often about balancing clinical needs with the lifestyle of each patient. Please join our upcoming symposium, Focus on Factor, at this years Thrombosis & Hemostasis Summit of North America (THSNA). During this time, Joanna Davis, MD and Guy Young, MD will share clinical data on treatment options of hemophilia A and hemophilia B. Q&A will follow the presentation.



IMMUNE THROMBOCYTOPENIA: EXPERT GUIDANCE TO INTEGRATE EMERGING THERAPIES INTO CLINICAL PRACTICE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom VI

This 1. 0-hour, CME-certified live satellite symposium will feature expert faculty presentations and discussions on integrating established and emerging therapies into the clinical management of immune thrombocytopenia (ITP). Topics that will be discussed will include treatment considerations for patients who are newly diagnosed with ITP, strategies for the optimal selection and sequencing of therapies for patients with progressing ITP, and the integration of novel and emerging therapies into the treatment of ITP. The faculty presentations and discussions also will feature expert guidance on the application of current clinical algorithms and evidence-based guidelines to the management of steroid-unresponsive ITP and considerations for treating ITP in special patient populations, such as children and those with chronic liver disease. These presentations will highlight key abstracts presented at THSNA 2022. Of importance, the faculty presenters will have the opportunity to engage in a lively panel discussion while answering pressing questions from the audience.